184 related articles for article (PubMed ID: 35875610)
1. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
[TBL] [Abstract][Full Text] [Related]
2. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
5. LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Petrilli A; Copik A; Posadas M; Chang LS; Welling DB; Giovannini M; Fernández-Valle C
Oncogene; 2014 Jul; 33(27):3571-82. PubMed ID: 23934191
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells.
Hardin HM; Dinh CT; Huegel J; Petrilli AM; Bracho O; Allaf AM; Karajannis MA; Griswold AJ; Ivan ME; Morcos J; Gultekin SH; Telischi FF; Liu XZ; Fernandez-Valle C
Mol Cancer Ther; 2023 Nov; 22(11):1280-1289. PubMed ID: 37527526
[TBL] [Abstract][Full Text] [Related]
7. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
Li M; Hu Y; Wang J; Xu Y; Hong Y; Zhang L; Luo Q; Zhen Z; Lu S; Huang J; Zhu J; Zhang Y; Que Y; Sun F
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063204
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.
Fuse MA; Plati SK; Burns SS; Dinh CT; Bracho O; Yan D; Mittal R; Shen R; Soulakova JN; Copik AJ; Liu XZ; Telischi FF; Chang LS; Franco MC; Fernandez-Valle C
Mol Cancer Ther; 2017 Nov; 16(11):2387-2398. PubMed ID: 28775147
[TBL] [Abstract][Full Text] [Related]
9. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
11. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
12. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
13. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
14. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
15. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
[TBL] [Abstract][Full Text] [Related]
16. CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.
Tu T; Huang J; Lin M; Gao Z; Wu X; Zhang W; Zhou G; Wang W; Liu W
Int J Mol Med; 2019 Nov; 44(5):1789-1800. PubMed ID: 31545402
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Inhibition of PI3K and PAK in Preclinical Models of Neurofibromatosis Type 2-related Schwannomatosis.
Fernandez-Valle C; Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin H
Res Sq; 2023 Oct; ():. PubMed ID: 37886501
[TBL] [Abstract][Full Text] [Related]
19. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
20. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
